Insights Into Prostate Cancer 2022
Perspectives on drivers in treatment decisions in the management of prostate cancer
Southwest – March 16, 2022
Faculty Chair
Scott Tagawa, MD, MS, FACP
Weill Cornell Medical Center, New York, NY, USA
Central – March 23, 2022
Faculty Chair
Scott Tagawa, MD, MS, FACP
Weill Cornell Medical Center, New York, NY, USA
Southeast – May 26, 2022
Faculty Chair
Scott Tagawa, MD, MS, FACP
Weill Cornell Medical Center, New York, NY, USA
Northeast – August 20, 2022
Faculty Chair
Alicia Morgans, MD, MPH
Dana-Farber Cancer Institute, Boston, MA, USA
Northwest – November 19, 2022
Faculty Chair
Evan Yu, MD
Fred Hutch Cancer Center, Seattle, WA, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Philadelphia, PA
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of prostate cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: apalutamide, darolutamide, enzalutamide, androgen deprivation therapy, docetaxel, abiraterone, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
